# Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

> **NCT03113994** · PHASE2 · TERMINATED · sponsor: **Dr. B. Catharine. Craven** · enrollment: 8 (actual)

## Conditions studied

- Spinal Cord Injuries
- Osteoporosis
- Metabolic Syndrome

## Interventions

- **DRUG:** Rosuvastatin Calcium
- **DRUG:** Placebo Oral Tablet
- **DIETARY_SUPPLEMENT:** Coenzyme Q10
- **DIETARY_SUPPLEMENT:** Calcium Carbonate
- **DIETARY_SUPPLEMENT:** Vitamin D

## Key facts

- **NCT ID:** NCT03113994
- **Lead sponsor:** Dr. B. Catharine. Craven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-26
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** COVID-19 Pandemic
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113994, "Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03113994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*